Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso BM, Sensi SL, Mansur RB, Rosenblat JD, Martinotti G, McIntyre RS. d'Andrea G, et al. Among authors: clerici m. J Affect Disord. 2024 Mar 1;348:314-322. doi: 10.1016/j.jad.2023.12.038. Epub 2023 Dec 23. J Affect Disord. 2024. PMID: 38145840
Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia.
Cuomo A, Aguglia E, Biagini S, Carano A, Clerici M, D'Agostino A, De Filippis S, De Giorgi S, Goracci A, Libri C, Lombardi F, Lupi M, Maina G, Martinotti G, Nigro P, Pettorruso M, Ricci V, Rossi E, Russo F, Fagiolini A; Italian Clinical Psychopharmacology Working Group. Cuomo A, et al. Among authors: clerici m. J Clin Psychopharmacol. 2023 Jan-Feb 01;43(1):35-38. doi: 10.1097/JCP.0000000000001629. J Clin Psychopharmacol. 2023. PMID: 36584247
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Chiappini S, d'Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, Barlati S, Pettorruso M, Sensi S, Clerici M, Dell'Osso B, Vita A, Martinotti G. Chiappini S, et al. Among authors: clerici m. Eur Neuropsychopharmacol. 2023 Sep;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011. Epub 2023 May 4. Eur Neuropsychopharmacol. 2023. PMID: 37148637 Free article.
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
d'Andrea G, Chiappini S, McIntyre RS, Stefanelli G, Carullo R, Andriola I, Zanardi R, Martiadis V, Sensi SL, Sani G, Clerici M, Di Lorenzo G, Vita A, Pettorruso M, Martinotti G. d'Andrea G, et al. Among authors: clerici m. Am J Geriatr Psychiatry. 2023 Dec;31(12):1032-1041. doi: 10.1016/j.jagp.2023.06.016. Epub 2023 Jul 8. Am J Geriatr Psychiatry. 2023. PMID: 37479669 Free article.
Ecological monitoring of physical activity, emotions and daily life activities in schizophrenia: the DiAPAson study.
Zarbo C, Rota M, Calza S, Crouter SE, Ekelund U, Barlati S, Bussi R, Clerici M, Placenti R, Paulillo G, Pogliaghi S, Rocchetti M, Ruggeri M, Starace F, Zanolini S, Zamparini M, de Girolamo G; DiAPAson Collaborators. Zarbo C, et al. Among authors: clerici m. BMJ Ment Health. 2023 Sep;26(1):e300836. doi: 10.1136/bmjment-2023-300836. BMJ Ment Health. 2023. PMID: 37666578 Free PMC article.
Interplay between negative symptoms, time spent doing nothing, and negative emotions in patients with schizophrenia spectrum disorders: results from a 37-site study.
D'Anna G, Zarbo C, Cardamone G, Zamparini M, Calza S, Rota M, Correll CU, Rocchetti M, Starace F, de Girolamo G; DIAPASON collaborators. D'Anna G, et al. Schizophrenia (Heidelb). 2023 Sep 21;9(1):63. doi: 10.1038/s41537-023-00372-x. Schizophrenia (Heidelb). 2023. PMID: 37735175 Free PMC article.
1,293 results